Dunhill Financial’s Vaxcyte PCVX Stock Holding History

Dunhill Financial’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$131	Hold	2	–	–	﹤0.01%	1333
2026 Q1	$131	Hold	2	–	–	﹤0.01%	1335
2025 Q4	$104	Buy	+2	New	+$89	﹤0.01%	1375

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Dunhill Financial's PCVX Position: Q2 2026 in Review

Dunhill Financial held its Vaxcyte (PCVX) position steady in Q2 2026 at 2 shares worth $131. The position accounts for ﹤0.01% of the portfolio, ranked #1333.

Dunhill Financial first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Dunhill Financial held 2 shares of Vaxcyte worth $131 as of Q2 2026.
Dunhill Financial left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1333 holding.
Dunhill Financial first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.